ArQule, Inc. (ARQL) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ArQule, Inc. (ARQL)

ARQL 20.00

0.0%

Jan 16 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: tuck who wrote (498)	6/5/2010 2:46:51 PM
From: scaram(o)uche	Read Replies (1) of 545

>> Any idea why this is significant? << Well..... my data set is old.... aria used to bemoan that molecules that bound to the atp binding site were promiscuous?? I am out of my league. Would be best if TD, BJ, an arql expert, or ????? chimed in. But a molecule can block activity at an active site without actually binding to the site... allosterism. So the advantage would be specificity? In the pre-Reg FD days, we could get excellent answers to questions like yours just by going to IR, and asking them to solicit a two sentence explanation/answer from the bench grunts. Sorry, can't really help. Best! Rick

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next